Lilly wins FDA approval for lung cancer drug
This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.